Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

34.83 +0.18 (+0.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,414,294
Open 34.75
Bid (Size) 34.22 (3)
Ask (Size) 35.02 (1)
Prev. Close 34.65
Today's Range 34.40 - 35.00
52wk Range 19.20 - 36.60
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNTech Stock Got A IBD RS Rating Lift
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
Vericel Stock Sees RS Rating Shoot Higher
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily

Performance

YTD
+45.55%
+45.55%
1 Month
+21.53%
+21.53%
3 Month
+32.28%
+32.28%
6 Month
+65.86%
+65.86%
1 Year
+64.14%
+64.14%

More News

Read More
NASDAQ:EXEL is an undervalued gem with solid fundamentals.
Via Chartmill
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
3 Magnificent Stocks Under $100 to Buy in November
Via The Motley Fool
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?
Via Benzinga
Earnings Preview: Exelixis
Via Benzinga
1 No-Brainer Stock to Buy With $40
Via The Motley Fool
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Exelixis (EXEL) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Biotech Momentum Trades For The Q4 Rally
Via Talk Markets
Analyst Ratings For Exelixis
Via Benzinga
Navigating 16 Analyst Ratings For Exelixis
Via Benzinga
Key Takeaways From Exelixis Analyst Ratings
Via Benzinga
A Closer Look at 5 Analyst Recommendations For Exelixis
Via Benzinga
Momentum Has Narrowed Again, Significantly
Via Talk Markets
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
Via Talk Markets
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
2 Growth Stocks to Buy With Less Than $100
Via The Motley Fool
Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
From Exelixis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.